Gastroparesis, or symptomatic delayed gastric emptying in the absence of mechanical obstruction, is a challenging and increasingly identified syndrome. Medical options are limited and the only medication approved by t...Gastroparesis, or symptomatic delayed gastric emptying in the absence of mechanical obstruction, is a challenging and increasingly identified syndrome. Medical options are limited and the only medication approved by the Food and Drug Administration for treatment of gastroparesis is metoclopramide, although other agents are frequently used off label. With this caveat, first-line treatments for gastroparesis include dietary modifications, antiemetics and promotility agents, although these therapies are limited by suboptimal efficacy and significant medication side effects. Treatment of patients that fail first-line treatments represents a significant therapeutic challenge. Recent advances in endoscopic techniques have led to the development of a promising novel endoscopic therapy for gastroparesis via endoscopic pyloromyotomy, also referred to as gastric per-oral endoscopic myotomy or per-oral endoscopic pyloromyotomy. The aim of this article is to review the technical aspects of the per-oral endoscopic myotomy procedure for the treatment of gastroparesis, provide an overview of the currently published literature, and outline potential next directions for the field.展开更多
Per a 9是美洲大蠊主要过敏原蛋白之一。通过生物信息学方法了解美洲大蠊过敏原蛋白Per a 9的结构特征,为蟑螂变态反应性疾病的诊断和治疗提供线索。BLAST得到Per a 9相似序列,构建同源进化树,结果显示美洲大蠊Per a 9与德国小蠊精氨酸...Per a 9是美洲大蠊主要过敏原蛋白之一。通过生物信息学方法了解美洲大蠊过敏原蛋白Per a 9的结构特征,为蟑螂变态反应性疾病的诊断和治疗提供线索。BLAST得到Per a 9相似序列,构建同源进化树,结果显示美洲大蠊Per a 9与德国小蠊精氨酸激酶在进化上具有较近的亲缘关系。Per a 9主要为α+β结构的亲水性蛋白,其主要抗原表位集中于33—46、55—74、89—117、123—135、199—217、235—243、251—266、286—354区域。Motif预测其具有1个鸟嘌呤磷酸转移酶活性位点,6个蛋白激酶C磷酸化位点,7个酪氨酸激酶II磷酸化位点和2个N豆蔻酰化位点。其预测的三维结构基本能反应Per a 9真实的空间构象,这将为今后进一步了解和掌握Per a 9结构和功能的关系打下理论基础。展开更多
文摘Gastroparesis, or symptomatic delayed gastric emptying in the absence of mechanical obstruction, is a challenging and increasingly identified syndrome. Medical options are limited and the only medication approved by the Food and Drug Administration for treatment of gastroparesis is metoclopramide, although other agents are frequently used off label. With this caveat, first-line treatments for gastroparesis include dietary modifications, antiemetics and promotility agents, although these therapies are limited by suboptimal efficacy and significant medication side effects. Treatment of patients that fail first-line treatments represents a significant therapeutic challenge. Recent advances in endoscopic techniques have led to the development of a promising novel endoscopic therapy for gastroparesis via endoscopic pyloromyotomy, also referred to as gastric per-oral endoscopic myotomy or per-oral endoscopic pyloromyotomy. The aim of this article is to review the technical aspects of the per-oral endoscopic myotomy procedure for the treatment of gastroparesis, provide an overview of the currently published literature, and outline potential next directions for the field.
文摘Per a 9是美洲大蠊主要过敏原蛋白之一。通过生物信息学方法了解美洲大蠊过敏原蛋白Per a 9的结构特征,为蟑螂变态反应性疾病的诊断和治疗提供线索。BLAST得到Per a 9相似序列,构建同源进化树,结果显示美洲大蠊Per a 9与德国小蠊精氨酸激酶在进化上具有较近的亲缘关系。Per a 9主要为α+β结构的亲水性蛋白,其主要抗原表位集中于33—46、55—74、89—117、123—135、199—217、235—243、251—266、286—354区域。Motif预测其具有1个鸟嘌呤磷酸转移酶活性位点,6个蛋白激酶C磷酸化位点,7个酪氨酸激酶II磷酸化位点和2个N豆蔻酰化位点。其预测的三维结构基本能反应Per a 9真实的空间构象,这将为今后进一步了解和掌握Per a 9结构和功能的关系打下理论基础。
